ENLV
Enlivex Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.39
−4.79%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.44
From 52W high−99.52%
Volume15913.00
Market cap$2.13M
P/E (TTM)0.0x
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.44
From 52W high
−99.52%
Volume
15913.00
Market cap
$2.13M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
0.0x
RSI (14)
12.4
MomentumView details →
1D Return
−4.79%
YTD Return
−99.15%
SummaryUpdated Jun 1, 2026
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) is an Israeli clinical-stage biotechnology company founded in 2005 and headquartered in Nes Ziona, Israel. The company went public in 2014 and specializes in developing innovative cell-based immunotherapies focused on macrophage reprogramming. Enlivex operates as a pure-play research and development company with no current revenue, dedicating its resources to advancing its lead therapeutic candidate through clinical trials for life-threatening conditions including sepsis and solid tumors.
Similar companies
Latest newsMore news →
Enlivex reported 12-month Phase I/IIa trial data showing a clinically meaningful response in 79.2% of patients aged 64 and older treated with Allocetra, compared with 47.6% in the placebo group.2d agoEnlivex reported that 135 of 182 planned patients had been randomized and received their first Allocetra injection in its Phase 2b knee osteoarthritis trial.7d ago